Share this post on:

AlmiRNA(s)DovepressmiR1273p, miR-148b, miR376a, miR376c, miR4093p, miR652, miRsubmit your manuscript | www.dovepress.commiR133a, miR-148bmiRmiR-148b, miR376c, miR4093p, miRmiR-155, miRmiRmiRNotes: This really is a representative sample of 20 current research discovered on a PubMed query (breast cancer blood miRNA miR) that describe individual miRNAs or miRNA signatures possessing possible application for early disease detection. Research with fewer than 20 BC situations had been excluded. Although these signatures mainly reflect larger amounts of circulating miRNAs, some miRNAs are detected at reduce levels in blood samples of BC sufferers. Blood collection was performed before surgery unless otherwise indicated. miRNAs shown in bold indicate a recurrent presence in a minimum of three independent studies. Abbreviations: BC, breast cancer; DCiS, ductal carcinoma in situ; eR, estrogen receptor; LN, lymph node status; miRNA, microRNA; qRTPCR, quantitative realtime polymerase chain reaction.Breast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 miRNArelated risk loci connected with BCGene locus MIR27A SNP rs895919 *C Comments Population Asians Caucasians Jewish BRCA2 carriers Caucasian Asians Caucasians Chinese (young) Chinese Asians Caucasians African order Protein kinase inhibitor H-89 dihydrochloride Americans African Americans european Americans Chinese Chinese African Americans european Americans African Americans european Americans italian Caucasians Chinese Asians Caucasians Asians Asians Caucasians Chinese Asians Caucasians Chinese Asians Caucasians African Americans African Americans Korean italian and German Asians Caucasians Brazilian Caucasian Chinese and Korean Chinese Chinese African Americans european Americans Asians Caucasians African Americans european Americans African a0023781 Americans African Americans european Americans African Americans european Americans Asians Caucasians Clinical observation No purchase Hesperadin danger association Protective dar.12324 elevated risk Decreased danger No danger association Decreased threat Decreased danger Decreased threat No risk association No threat association increased survival No risk association Decreased general threat enhanced risk elevated risk No threat association increased general threat Decreased risk of eR+ BC No risk association earlier age of onset No threat association No danger association No danger association No threat association Decreased danger (C allele) No threat association No danger association No risk association No danger association No risk association No risk association No risk association No danger association Decreased threat Decreased risk Survival of HeR2+ instances No risk association Decreased threat No danger association Decreased danger Decreased threat Decreased danger improved threat increased danger No threat association No danger association No risk association No threat association Decreased risk of eR- BC No risk association improved survival elevated threat of eR- BC No danger association No danger association enhanced general threat No danger association No threat association Reference 141 142 143 144 35 34 31 145 33 38 38 33 33 146 147 83 38 144 31 36 38 36 31 145 145 148 37 141 149 147 32 36 83 33 31 33 145 33 33rs895819 A/GpremiRNA premiRNA premiRNA premiRNAMIR34B cluster MIR100 MIR101-2 MIR106B MIR122A MIR146Ars4938723 T/C rs1834306 G/A rs1053872 C/G rs462480 A/C rs1527423 A/G rs17669 A/G rs2910164 G/C Key transcript Main transcriptMIRrs2292832 T/GMIR185 MIR196A-rs2008591 C/T rs887205 A/G rs11614913 T/CMIR204 MIR206 MIR219 MIR331 MIRrs7861254 G rs6920648 A/G rs107822 G/A rs.AlmiRNA(s)DovepressmiR1273p, miR-148b, miR376a, miR376c, miR4093p, miR652, miRsubmit your manuscript | www.dovepress.commiR133a, miR-148bmiRmiR-148b, miR376c, miR4093p, miRmiR-155, miRmiRmiRNotes: That is a representative sample of 20 current studies located on a PubMed query (breast cancer blood miRNA miR) that describe individual miRNAs or miRNA signatures possessing possible application for early disease detection. Research with fewer than 20 BC situations were excluded. When these signatures mostly reflect higher amounts of circulating miRNAs, some miRNAs are detected at lower levels in blood samples of BC sufferers. Blood collection was performed before surgery unless otherwise indicated. miRNAs shown in bold indicate a recurrent presence in at the very least 3 independent studies. Abbreviations: BC, breast cancer; DCiS, ductal carcinoma in situ; eR, estrogen receptor; LN, lymph node status; miRNA, microRNA; qRTPCR, quantitative realtime polymerase chain reaction.Breast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable 2 miRNArelated danger loci associated with BCGene locus MIR27A SNP rs895919 *C Comments Population Asians Caucasians Jewish BRCA2 carriers Caucasian Asians Caucasians Chinese (young) Chinese Asians Caucasians African Americans African Americans european Americans Chinese Chinese African Americans european Americans African Americans european Americans italian Caucasians Chinese Asians Caucasians Asians Asians Caucasians Chinese Asians Caucasians Chinese Asians Caucasians African Americans African Americans Korean italian and German Asians Caucasians Brazilian Caucasian Chinese and Korean Chinese Chinese African Americans european Americans Asians Caucasians African Americans european Americans African a0023781 Americans African Americans european Americans African Americans european Americans Asians Caucasians Clinical observation No danger association Protective dar.12324 enhanced danger Decreased threat No risk association Decreased threat Decreased risk Decreased threat No risk association No threat association elevated survival No risk association Decreased overall danger elevated danger enhanced risk No risk association elevated general threat Decreased threat of eR+ BC No danger association earlier age of onset No danger association No risk association No risk association No danger association Decreased threat (C allele) No danger association No risk association No risk association No risk association No risk association No risk association No threat association No threat association Reduced danger Lowered threat Survival of HeR2+ cases No risk association Decreased risk No threat association Decreased danger Decreased threat Decreased danger improved risk enhanced risk No risk association No threat association No risk association No danger association Decreased risk of eR- BC No risk association enhanced survival enhanced danger of eR- BC No danger association No threat association elevated all round risk No threat association No risk association Reference 141 142 143 144 35 34 31 145 33 38 38 33 33 146 147 83 38 144 31 36 38 36 31 145 145 148 37 141 149 147 32 36 83 33 31 33 145 33 33rs895819 A/GpremiRNA premiRNA premiRNA premiRNAMIR34B cluster MIR100 MIR101-2 MIR106B MIR122A MIR146Ars4938723 T/C rs1834306 G/A rs1053872 C/G rs462480 A/C rs1527423 A/G rs17669 A/G rs2910164 G/C Main transcript Primary transcriptMIRrs2292832 T/GMIR185 MIR196A-rs2008591 C/T rs887205 A/G rs11614913 T/CMIR204 MIR206 MIR219 MIR331 MIRrs7861254 G rs6920648 A/G rs107822 G/A rs.

Share this post on:

Author: Proteasome inhibitor